Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTAX01
- Development stage
- Phase 3
- Lead developer
- BioTissue
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Administration
- Topical
01
Overview
TTAX01 is a cryopreserved human umbilical cord (UC) product derived from donated placental tissue following healthy, full-term caesarian section births. It is processed using the CRYOTEK method to preserve biological activity. The product is intended for use as a wound covering in the treatment of complex, non-healing diabetic foot ulcers (DFU), particularly Wagner Grades 3 and 4. Its mechanism of action involves providing an extracellular matrix that supports wound healing by delivering growth factors and anti-inflammatory components present in the UC tissue. Clinical studies have shown that application of TTAX01 to well-debrided wounds, alongside systemic antibiotics and aggressive debridement, results in higher rates of complete healing compared to standard care alone. The drug has completed Phase 3 trials for diabetic foot infection and non-healing wounds[1][2][3][4][5][6][7].
- Brand names
- NEOX CORD 1KNeox 1KNeox1KNeox-1K
- Other names
- cryopreserved human umbilical cordcryopreserved human amniotic membrane and umbilical cord matrix
Beyond the preview
Go deeper on TTAX01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTAX01.